Scholarlink

Background <p>Mitochondrial dysfunction represents a recognized hallmark of cancer; however, the underlying molecular mechanisms contributing to this process in lung adenocarcinoma (LUAD) remain incompletely understood.</p> Methods <p>Differentially expressed genes (DEGs) in LUAD were identified by integrating datasets (GSE7670, GSE10072, and GSE32863), and were subsequently cross-referenced with mitochondria-related genes from the MitoCarta3.0 database. Hub genes were identified using the least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) algorithms. LUAD cell lines and xenograft models with stable overexpression of acyl-CoA dehydrogenase long chain (ACADL) were subsequently established. To assess the involvement of the FOXO3a/PUMA signaling axis in mediating tumor suppression, the selective FOXO3a inhibitor AS1842856 was employed.</p> Results <p>Eight hub genes (ACADL, BIK, CAT, COX7A1, PAICS, PDK4, PRDX4, and PYCR1) demonstrated high diagnostic accuracy for LUAD, with area under the curve (AUC) values exceeding 0.80. ACADL, CAT, PDK4, and COX7A1 were significantly downregulated, whereas BIK, PAICS, PYCR1, and PRDX4 were upregulated in A549 and H1299 LUAD cell lines. Functional assays revealed that overexpression of ACADL suppressed cell proliferation, migration, and invasion, while inducing apoptosis in LUAD cells. Mechanistically, ACADL impaired mitochondrial bioenergetics by reducing intracellular ATP levels and promoting reactive oxygen species (ROS) accumulation. Additionally, ACADL enhanced mitochondrial fission by upregulating Drp1 and Fis1, and downregulating Mfn2 expression. Further mechanistic investigations indicated that ACADL activated the FOXO3a/PUMA signaling axis. In vivo, ACADL expression markedly inhibited tumor growth and disrupted mitochondrial homeostasis, an effect that was significantly attenuated upon administration of the FOXO3a inhibitor AS1842856.</p> Conclusion <p>ACADL functions as a mitochondria-associated tumor suppressor that impedes LUAD progression through activation of the FOXO3a/PUMA signaling pathway, underscoring its potential as a therapeutic target for LUAD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated transcriptomic analysis and experimental validation identify ACADL as a mitochondrial tumor suppressor via the FOXO3a/PUMA axis in lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月5日

查看全文
  • Ying Wang,
  • Yan Ding

摘要

Background

Mitochondrial dysfunction represents a recognized hallmark of cancer; however, the underlying molecular mechanisms contributing to this process in lung adenocarcinoma (LUAD) remain incompletely understood.

Methods

Differentially expressed genes (DEGs) in LUAD were identified by integrating datasets (GSE7670, GSE10072, and GSE32863), and were subsequently cross-referenced with mitochondria-related genes from the MitoCarta3.0 database. Hub genes were identified using the least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE) algorithms. LUAD cell lines and xenograft models with stable overexpression of acyl-CoA dehydrogenase long chain (ACADL) were subsequently established. To assess the involvement of the FOXO3a/PUMA signaling axis in mediating tumor suppression, the selective FOXO3a inhibitor AS1842856 was employed.

Results

Eight hub genes (ACADL, BIK, CAT, COX7A1, PAICS, PDK4, PRDX4, and PYCR1) demonstrated high diagnostic accuracy for LUAD, with area under the curve (AUC) values exceeding 0.80. ACADL, CAT, PDK4, and COX7A1 were significantly downregulated, whereas BIK, PAICS, PYCR1, and PRDX4 were upregulated in A549 and H1299 LUAD cell lines. Functional assays revealed that overexpression of ACADL suppressed cell proliferation, migration, and invasion, while inducing apoptosis in LUAD cells. Mechanistically, ACADL impaired mitochondrial bioenergetics by reducing intracellular ATP levels and promoting reactive oxygen species (ROS) accumulation. Additionally, ACADL enhanced mitochondrial fission by upregulating Drp1 and Fis1, and downregulating Mfn2 expression. Further mechanistic investigations indicated that ACADL activated the FOXO3a/PUMA signaling axis. In vivo, ACADL expression markedly inhibited tumor growth and disrupted mitochondrial homeostasis, an effect that was significantly attenuated upon administration of the FOXO3a inhibitor AS1842856.

Conclusion

ACADL functions as a mitochondria-associated tumor suppressor that impedes LUAD progression through activation of the FOXO3a/PUMA signaling pathway, underscoring its potential as a therapeutic target for LUAD.